“Unlock the Potential of Your Immune System”

py development, making “cold” tumors more responsive to immunotherapy. What are the latest advancements in immunotherapy response testing?

“Unlock the Potential of Your Immune System” (Simo Arredouani, PhD) [#135] ●Blood test advancements : Using blood draws instead of your tumor tissue enables less invasive monitoring of your cancer, which is particularly useful for hard-to-access tumors like brain metastases.

●High-resolution immune system analysis : Detailed sequencing of white blood cells (T cell and B cell receptors) and using AI and machine learning can identify response patterns and identify unique antigens for potential vaccine or cell therapy development.

●Early response and adverse event prediction : Identifying immune system (T cell receptor) signatures that correlate with immunotherapy response, potentially predicting response within 2-3 months of treatment start and helping you decide whether to continue or switch treatments; tracking your immune repertoire changes before and after treatment can identify potential side effects and adverse events early and personalize your treatment.

What are the key challenges in applying immune system analysis to rare cancer types with low mutational burden? ●Limited existing data : Rare cancers have fewer samples, which makes it harder to develop reliable AI models and predictive signatures.

●Slower treatment development : Creating targeted therapies like TCR-T cell treatments requires extensive validation and may take longer for rare cancer types for target antigen identification and validation. How can you access Omniscope's groundbreaking technology for your personal healthcare journey?

●Pursue their new comprehensive immune system health report for research on professional athletes, currently $2,000-$5,000 for one-year access and requires traveling to Barcelona for blood sample ●Ask your oncologist whether non-standard cancer treatment response prediction would be useful for you. How can you learn more?

●Go to Omniscope's website and create a free account to view their sample data, research, and videos. ●See our discussion with Keith Wharton "Bringing Novel Immune System Tests from Research to Clinical Use" [#28] ●See our discussion with Heather Tomlinson “How MSI and Other Tests Can Guide Immunotherapies for Cancer Treatment” [#43] ●Contact Simo Arredouani at simo@omniscope.

ai for the most current logistics and prices for accessing their consumer-facing immune health services.

“Unlock the Potential of Your Immune System” (Simo Arredouani, PhD) [#135] medical treatment, product, or course of action. You should always consult a doctor about your

recommendations or medical advice by Cancer Patient Lab, its principals, presenters, participants, or representatives for any

“Unlock the Potential of Your Immune System” (Simo Arredouani, PhD) [#135] medical treatment, product, or course of action. You should always consult a doctor about your specific situation before pursuing any health care program, treatment, product or other course of action that might affect your health.

“Unlock the Potential of Your Immune System” (Simo Arredouani, PhD) [#135] Meeting Notes KEYWORDS Cancer immunology, T cell receptors, B cell receptors, Omniscope, single cell genomics, AI models, immune system, cancer therapy, TCR sequences, minimal residual disease, autoimmune disease, vaccine development, bone marrow transplant, immune health, FC Barcelona.

SPEAKERS Simo Arredouani (75%), Brad Power (9%), Nina Senna (7%), Richard Anders (3%), Rick Davis (2%), Cindy Ness (2%), Alane Watkins (1%), Sandra Balladares (1%) CHAT CONTRIBUTORS Alane Watkins, Nina Senna, Koryn DelPrince, Rick Davis, Helen, Sandra Balladares, David Plunkett SUMMARY Simo Arredouani, a cancer immunologist, discussed Omniscope's technology, which processes 1 million cells per sample, 100 times more than competitors.

This technology aids in diagnostics and therapeutics, including T cell and B cell therapies. It can detect minimal residual disease, autoimmune diseases, and viral infections. Arredouani highlighted a collaboration with FC Barcelona to track athletes' immune health. The technology can predict treatment responses, potentially saving time and money.

Omniscope's early access program for immune health assessments costs around $2,000-$5,000. The goal is to stratify patients and improve cancer treatment efficacy. OUTLINE Introductions, Simo Arredouani's Background, and Omniscope Overview ●Our purpose was to discuss cancer immunology with Simo Arredouani, a cancer immunologist and PhD in immunology from Harvard Medical School.

●Simo introduced himself and explained his background in cancer immunology and immunotherapy, including his work at Genius Bio and Tele Therapeutics. ●Simo introduced Omniscope, a tech-bio company based in Barcelona, and mentioned key team members like Vijay (CEO), Lynette (Chief Growth Officer), Holger (Scientist), and Matt (Chief Information Officer), and Nina.

●The immune system is important in fighting cancer, and T cells and B cells have a role in immunity. ●Omniscope's technology processes 100 times more cells than competitors, allowing for detailed analysis of TCR and BCR sequences.

“Unlock the Potential of Your Immune System” (Simo Arredouani, PhD) [#135] ●Omniscope's technology can be used for diagnostics, therapeutics, target discovery, and licensing TCR sequences for T cell therapy. ●Examples of how the technology can detect minimal residual disease in various cancers and decipher the autoimmune nature of diseases like small fiber neuropathy.

] ●Omniscope's technology can be used for diagnostics, therapeutics, target discovery, and licensing TCR sequences for T cell therapy. ●Examples of how the technology can detect minimal residual disease in various cancers and decipher the autoimmune nature of diseases like small fiber neuropathy.

●The ability to detect viral infections and monitor immune responses to antiviral treatments using Omniscope's high-resolution detection. ●The technology can classify different cancers based on T cell and B cell signatures and rank patients on an immunological scale.

Case Studies and Collaborations ●Simo shares a study on brain metastasis, showing the high overlap between tumor, cerebrospinal fluid, and blood samples, making blood testing a reliable alternative. ●He discusses the use of Omniscope's technology in cancer vaccines, which can track the evolution of the immune response with high accuracy.

●Simo describes a collaboration with Immacor, which has an FDA-approved TCR bispecific for advanced melanoma, and how Omniscope helped identify mechanisms of action and adverse events. ●He explains how the technology can predict adverse events in immunotherapy and identify drug efficacy early in treatment.

T Cell and B Cell Repertoires ●Richard Anders asked about the diversity of T cell receptors and how Omniscope deals with HLA types. Simo explained the importance of HLA alleles and the challenges of predicting TCR sequences without considering HLA. ●Richard also inquires about the isotypes of TCRs and antibodies, and Simo clarifies that they focus on alpha-beta TCRs.

●Brad and Simo discuss the importance of understanding HLA for bone marrow transplants and the potential for Omniscope's technology to track immune rejection and GVHD. Rare Cancers and Therapeutic Applications ●Alane Watkins asks about the application of Omniscope's technology to rare cancers like thymoma, which have few mutations.

Simo explains that while vaccines may not be viable, TCR T cell therapies can be developed using Omniscope's technology. ●Helen asks about monitoring the efficacy of Avastin for rare ovarian cancer. Nina explains that while they have experience with similar monoclonal antibodies, they would need to conduct a clinical trial to develop a signature for predicting response.

●Simo adds that they are working on expanding their technology to other cancer types and therapies. Consumer Access and Future Directions ●Cindy Ness asks about the practical application of Omniscope's technology for patients. Simo explains that while it is not yet available as a standard clinical tool, they are working towards regulatory approval and collaboration with hospitals.

●Simo mentions a product for assessing immune health in the general population and a collaboration with FC Barcelona to track the immune health of professional athletes.

“Unlock the Potential of Your Immune System” (Simo Arredouani, PhD) [#135]